AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1α stabilization

Area of Science:

• Biochemistry
• Mitochondrial Biology
• Cancer Research

Background:

• Mitochondria play a crucial role in cancer progression, chemoresistance, and metastasis.
• Cancer cells exhibit unique metabolic profiles exploitable by targeted therapies.
• Mitochondrial-targeted anticancer molecule AG311 demonstrated prior anticancer and antimetastatic activity.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying AG311's efficacy by defining its effects on mitochondria.
• To identify specific mitochondrial targets of AG311.

Main Methods:

• Biochemical assays to determine AG311's interaction with mitochondrial complex I.
• Measurement of oxygen consumption rates in tumor tissue from AG311-treated mice.
• Evaluation of synergistic effects of AG311 with dichloroacetate (a PDK inhibitor).

Main Results:

• AG311 competitively inhibits mitochondrial complex I activity at the ubiquinone-binding site.
• AG311 treatment reduces oxygen consumption rate in tumor tissue.
• Combination therapy with AG311 and dichloroacetate shows synergistic cancer cell kill and reduced tumor growth.
• AG311 inhibits HIF-1α stabilization by increasing oxygen tension under hypoxic conditions.

Conclusions:

• AG311 exerts its antitumor effects, at least partially, through the inhibition of mitochondrial complex I.
• Targeting mitochondrial complex I with AG311 represents a potential therapeutic strategy for cancer treatment.
• The observed reduction in HIF-1α stabilization contributes to AG311's antitumor activity.